ITGA2B and breast cancer: However, two weeks after the injection with 4T1 breast cancer cells, the mice demonstrated increased activation of circulating platelets (P < 0.01 for the expression of activated GPIIb/IIIa complex and the binding of vWF and Fg) and elevated response to 20 μM ADP (P < 0.05 for CD62P and P < 0.01 for vWF and Fg) and 0.25 U/ml thrombin (P < 0.01 for CD62P and vWF) than those administered EpH4-Ev breast epithelium non-cancer cells (data not shown).